ResMed Inc. (ResMed): ResMed is a premier global enterprise founded in 1989 in San Diego, California, United States. Operating under CEO Mick Farrell, the company reported $4.68B in consolidated revenue and $1.02B in net income, managing over ResMed is the undisputed global market leader in continuous positive airway pressure (CPAP) devices, respiratory masks, and cloud-connected digital sleep health software, holding over 60% global market share in sleep apnea therapies across 140+ countries. in total assets. ResMed is the undisputed global market leader in continuous positive airway pressure (CPAP) devices, respiratory masks, and cloud-connected digital sleep health software, holding over 60% global market share in sleep apnea therapies across 140+ countries.
ResMed: Company Timeline
Dr. Peter Farrell establishes ResMed to commercialize Dr. Colin Sullivan's continuous positive airway pressure invention. [source]
Completes IPO under ticker symbol RMD, expanding global distribution across North America and Europe. [source]
Transfers primary US stock listing to the NYSE, solidifying institutional shareholder backing. [source]
Introduces active-cell cushion technology, setting an industry benchmark for mask comfort and seal integrity. [source]
Commercializes sleek S9 platform with Climate Control humidification, overcoming patient airway drying. [source]
Mick Farrell assumes leadership as CEO, initiating ResMed's strategic transformation into digital healthcare. [source]
Embeds built-in cellular connectivity in every device, launching the world's largest remote sleep monitoring network. [source]
Acquires leading out-of-hospital cloud software provider Brightree, establishing SaaS business unit. [source]
Expands SaaS footprint into long-term post-acute EHR, senior living, and home care software. [source]
Unveils AirSense 11 with touchscreen interface, digital Personal Therapy Assistant, and Care Check-In. [source]
Competitor Philips recalls millions of devices, driving unprecedented global demand and market share to ResMed. [source]
Acquires German out-of-hospital software provider, creating a European post-acute digital health pillar. [source]
Achieves record connected patient milestone on AirView, tracking billions of nights of sleep therapy. [source]
Delivers record financial performance with double-digit growth across masks, devices, and digital health software. [source]
What Is the History of ResMed?
The origins of ResMed date back to 1981 at the University of Sydney in Australia, where Dr. Colin Sullivan invented nasal continuous positive airway pressure (CPAP)—demonstrating that delivering pressurized room air through a nasal mask acted as a pneumatic splint, keeping upper airways open and curing obstructive sleep apnea. Recognizing the immense clinical potential of this discovery, Dr. Peter Farrell, a biomedical engineer and vice president of R&D at Baxter Healthcare, led an investment to license Sullivan's patents. In 1989, Dr. Farrell founded ResMed (short for 'Respiratory Medicine') in Sydney with nine employees to commercialize comfortable, whisper-quiet CPAP machines. The company's early years were characterized by pioneering engineering: replacing bulky industrial blowers with compact, microprocessor-controlled motors and designing ergonomic silicone masks. In 1995, ResMed completed an initial public offering on NASDAQ before dual-listing on the New York Stock Exchange and the Australian Securities Exchange (ASX). In 2014, under CEO Mick Farrell, ResMed executed a radical digital transformation by embedding cellular chips as a standard feature into every single AirSense 10 device, instantaneously creating the world's largest remote patient monitoring network in respiratory medicine. In the decades following its initial founding, ResMed navigated rapid industry evolutions, transitioning from early legacy operating paradigms to modern integrated operations. This sustained focus allowed the company to survive cyclical macroeconomic contractions, outpace regional incumbents, and establish deep institutional trust with demanding stakeholders. Through disciplined capital allocation, continuous internal innovation, and targeted strategic initiatives, ResMed built an enduring competitive moat anchored by proprietary technology, deep domain expertise, and sticky relationships that resist structural disruption.ResMed: Expert Analysis
Strategic Insight: Market Positioning & Economic Moat
ResMed's formidable economic moat is built upon four enduring structural pillars: (1) The AirView Cloud Network Effect: With over 20.5 million cloud-connected patient devices transmitting billions of nights of sleep data, AirView is deeply integrated into the daily billing and clinical workflows of HME providers and physicians. HMEs achieve 87% compliance rates with connected ResMed devices compared to ~50% with unmonitored systems, making provider switching economically irrational; (2) Unrivaled Brand Equity Post-Philips Recall: The multi-year recall and subsequent US consent decree banning Philips Respironics from selling sleep devices in the US permanently cemented ResMed as the undisputed, trusted market leader; (3) Mask Resupply Machine: Specialized automated resupply software (Brightree ReSupply) tracks patient cushion wear and insurance eligibility, automatically shipping fresh masks and tubing to patients, generating an annuity-like recurring revenue stream; and (4) Proprietary Acoustic and Algorithm IP: Advanced AutoSet algorithms continuously adjust pressure on a breath-by-breath basis while QuietAir woven-mesh venting delivers near-silent operation (25 dBA). ResMed's competitive moat is reinforced by deep customer switching costs, extensive proprietary operating assets, and mission-critical workflows that are deeply embedded into everyday client or partner operations. Displacing ResMed's established market footprint requires multi-year investments and significant operational risk, leading to industry-leading customer retention rates. By coupling proprietary systems with dedicated high-touch operational support and regulatory certifications, ResMed delivers an integrated experience that commodity market alternatives cannot replicate.ResMed: Founders
Dr. Peter Farrell
Founder, Former CEO & Chairman Emeritus
Dr. Peter Farrell founded ResMed in 1989 after acquiring the commercial rights to Dr. Colin Sullivan's continuous positive airway pressure prototype from Baxter Healthcare. Holding a PhD in bioengineering from the University of Washington, Farrell served as CEO from 1989 to 2013 and Executive Chairman until 2023, building ResMed into a global medtech titan.
How Does ResMed Make Money?
ResMed generates revenue across diversified commercial and operating segments:
1. Connected CPAP & Respiratory Flow Generators: Monetizes premium AirSense 11, AirCurve, and AirMini flow generators placed through durable medical equipment (DME) dealers, hospitals, and sleep clinics worldwide.
2. High-Margin Mask & Consumable Resupply Engine: Generates recurring, annuity-like sales from AirFit nasal, full-face, and pillow masks, replacement silicone cushions, headgear, filters, and heated humidification tubing.
3. Out-of-Hospital SaaS Subscriptions (Brightree): Monetizes cloud-based practice management, electronic billing, and automated patient resupply software subscriptions for home medical equipment providers.
4. Post-Acute Care Healthcare Software (MatrixCare): Sells electronic health record (EHR) and clinical workflow management software to senior living communities, skilled nursing facilities, and private home health agencies.
5. AirView Digital Healthcare Cloud Platform: Provides healthcare providers with remote patient compliance verification, telemonitoring, and automated prescription synchronization tools.
What Is ResMed's Competitive Advantage?
ResMed maintains critical economic advantages in its global industry:
20.5M+ Device AirView Cloud Network Effect: The world's largest remote patient monitoring network in respiratory medicine, creating immense clinical stickiness and automated insurance reimbursement verification.
Dominant Market Position Post-Philips Recall: Capturing over 60% global market share following competitor quality crises, establishing ResMed as the gold standard for clinical safety and device reliability.
Automated Mask Replenishment Infrastructure: Proprietary Brightree ReSupply software predicts patient cushion degradation and automates insurance re-orders, driving recurring high-margin sales.
Whisper-Quiet QuietAir Acoustic Technology: Proprietary woven-mesh acoustic vents and motor balancing deliver 25 dBA whisper-quiet operation, maximizing bed-partner sleep quality and patient compliance.
Extensive Global Regulatory and Distribution Moat: Commercial sales operations, localized clinical registrations, and direct medical supply chains operating across 140 countries.
Who Are ResMed's Main Competitors?
ResMed competes against major industry peers across key business sectors:
Philips Respironics: Historical primary global competitor in sleep therapy and mechanical ventilation, currently navigating recovery from a global product recall.
Fisher & Paykel Healthcare: New Zealand-based medical device manufacturer competing in sleep apnea masks, heated humidifiers, and respiratory care.
SomnoMed Limited: Oral appliance therapy manufacturer providing custom mandibular advancement devices as an alternative for mild sleep apnea.
Inspire Medical Systems: Innovator offering implantable hypoglossal nerve stimulation devices for patients unable to tolerate CPAP therapy.
What Companies Has ResMed Acquired?
| Year | Company | Value | Strategic Purpose | Outcome |
|---|---|---|---|---|
| 2022 | N/A | $1.0B | German provider of out-of-hospital software solutions for ambulatory nursing, elderly care, and therapists. | Integrated |
| 2018 | N/A | $750M | Long-term post-acute care EHR and senior living practice management software. | Integrated |
| 2016 | N/A | $800M | Cloud-based billing, patient resupply, and business management software for home medical equipment. | Integrated |
| 2019 | N/A | $225M | Digital sensor attachments for inhalers monitoring COPD and asthma medication adherence. | Integrated |
Who Leads ResMed?
Michael 'Mick' Farrell
CEO
Mick Farrell was appointed CEO in March 2013 and Chairman of the Board in January 2023. Having joined ResMed in 2000, Farrell championed the company's transformation into a cloud-connected digital health powerhouse and orchestrated major SaaS acquisitions including Brightree and MatrixCare.
Dr. Peter Farrell
Founder
Dr. Peter Farrell founded ResMed in 1989 in Sydney, Australia, guided its initial public offerings on NASDAQ and the NYSE, and served as CEO for 24 years before transitioning executive leadership to Mick Farrell.
Brett Sandercock
CFO
Brett Sandercock served as ResMed's Chief Financial Officer from January 2006 through 2024, steering global financial strategy, capital allocation, investor relations, and M&A financing across nearly two decades of continuous expansion.
Lucile Blaise
President
Lucile Blaise leads commercial strategy and operations for ResMed's core sleep and respiratory care business across Europe, Asia, and international markets, driving clinician engagement and digital therapy adoption.
Justin Leong
CPO
Justin Leong serves as Chief Product Officer, leading ResMed's product-led operating model, hardware engineering, algorithm development, and user experience across sleep therapy and respiratory health portfolios.
Bobby Ghoshal
Executive
Bobby Ghoshal leads ResMed's global out-of-hospital Software as a Service (SaaS) business, overseeing Brightree, MatrixCare, and MEDIFOX DAN to drive cloud innovation across post-acute care providers.
How Is ResMed Growing?
Under executive leadership, ResMed is executing several multi-year growth vectors:
1. Unlocking the Global Undiagnosed Sleep Apnea Market: Targeting the 900M+ undiagnosed sleep apnea sufferers worldwide through simplified home sleep testing and partnerships with consumer wearables.
2. Accelerating Global AirSense 11 Fleet Transition: Upgrading existing legacy CPAP install bases to the connected AirSense 11 platform across Europe, Japan, and North America.
3. Expanding Post-Acute SaaS Software in Europe: Scaling MEDIFOX DAN and MatrixCare software into ambulatory care providers, outpatient rehab clinics, and elderly nursing homes across Europe.
4. Leveraging AI for Personalized Patient Coaching: Using machine learning within the myAir app to detect therapy leaks, predict abandonment risk, and provide tailored motivational coaching.
5. Integrated Cardiovascular & Metabolic Disease Management: Partnering with cardiologists and endocrinologists to treat sleep disordered breathing as a primary driver of hypertension, stroke, and diabetes.
What Are the Biggest Risks Facing ResMed?
ResMed navigates industry, macroeconomic, and competitive headwinds:
Potential Impact of GLP-1 Anti-Obesity Therapies: Patient utilization of GLP-1 weight loss medications potentially altering obstructive sleep apnea severity or adoption velocity over multi-year horizons.
Potential Resurgence of Philips Respironics: Eventual resolution of regulatory consent decrees allowing Philips to reintroduce competitive sleep devices into international markets.
Medical Equipment Supplier Channel Consolidation: Large national HME chains merging, potentially demanding larger volume discounts on CPAP flow generators and mask consumables.
Global Supply Chain & Cellular Chip Component Risks: Availability of specialized microcontrollers, cellular communication modems, and medical silicones during global supply shortages.
ResMed: Quick Reference Q&A
Q: What does ResMed do and what is its core business?
A: ResMed (RMD) is a leading global enterprise software and technology provider in Medical Devices, Sleep Apnea, Respiratory Care, Digital Health, Cloud Healthcare SaaS, serving thousands of organizations worldwide with mission-critical cloud solutions that automate core operational workflows.
Q: How does ResMed make money?
A: ResMed operates a recurring SaaS subscription and technology licensing business model charging annual or per-user/volume fees for software access, alongside high-margin add-on modules, payments processing, and enterprise implementation services.
Q: Who founded ResMed and when was it established?
A: ResMed was established in 1989 in San Diego, California, United States. Founding leadership established the company to transform manual legacy processes into modern digital systems, driving widespread industry modernization.
Q: Who is the current CEO of ResMed?
A: Mick Farrell serves as Chief Executive Officer, directing corporate strategy, technology innovation, and global commercial operations across major enterprise accounts.
Q: What is ResMed's financial performance and revenue scale?
A: ResMed generates $4.68B in annual revenue with strong recurring cash flows, high gross margins, and expanding operating leverage across its core subscription product lines.
Q: What are ResMed's key competitive advantages?
A: ResMed's competitive moat includes AirSense 11 connected sleep devices, AirView digital health ecosystem with 20.5M+ cloud-connected patients, proprietary QuietAir and AirFit mask technologies, and out-of-hospital SaaS software platforms (Brightree, MatrixCare).. These structural advantages create high switching costs and formidable barriers to entry against potential competitors.
Q: Who are ResMed's primary competitors?
A: ResMed's main competitors include Philips Respironics & Fisher & Paykel Healthcare and other enterprise technology providers operating across the cloud software and digital transformation landscape.
Q: How does ResMed leverage artificial intelligence?
A: ResMed integrates machine learning and generative AI across its platform to automate repetitive tasks, summarize complex documents, detect anomalies, and deliver predictive business intelligence in real time.
Q: What is ResMed's long-term growth strategy?
A: ResMed's growth strategy focuses on expanding into high-growth international markets, deepening fintech and embedded payment solutions, scaling enterprise accounts, and investing in continuous AI innovation.
Q: Is ResMed a public or private company?
A: ResMed is publicly traded on the NYSE under the ticker symbol RMD, maintaining disciplined financial governance and transparent shareholder reporting.
